Risk factors for cataracts in systemic lupus erythematosus (SLE)

Rheumatology International

Volumn 35, Issue 4, 2015, Pages 701-708

  Alderaan, Khaled ^a,b   Sekicki, Vuk ^c   Magder, Laurence S ^d   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^c ST AGNES HOSPITAL   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cataract; Frequency; Predictor; Systemic lupus erythematosus

Indexed keywords

CHOLESTEROL; COMPLEMENT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; GLUCOCORTICOID;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CATARACT; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK FACTOR; SLEDAI; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; BLOOD PRESSURE; COMPLICATION; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD PRESSURE; CATARACT; FEMALE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDNISONE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84925513442     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3129-5     Document Type: Article

References (39)

1. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–851
2. Leske MC, Chylack LT Jr, Wu SY (1991) The lens opacities case–control study. Risk factors for cataract. Arch Ophthalmol 109:244–251
3. Hiller R, Sperduto RD, Ederer F (1986) Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol 124:916–925
4. Kanthan GL, Wang JJ, Rochtchina E, Tan AG, Lee A, Chia EM, Mitchell P (2008) Ten-year incidence of age-related cataract and cataract surgery in an older Australian population. The Blue Mountains Eye Study. Ophthalmology 115:808–814
5. West SK, Valmadrid CT (1995) Epidemiology of risk factors for age-related cataract. Surv Ophthalmol 39:323–334
6. Mares JA, Voland R, Adler R, Tinker L, Millen AE, Moeller SM, Blodi B, Gehrs KM, Wallace RB, Chappell RJ, Neuhouser ML, Sarto GE, CAREDS Group (2010) Healthy diets and the subsequent prevalence of nuclear cataract in women. Arch Ophthalmol 128:738–749
7. Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808
8. Carli L, Tani C, Querci F, Della Rossa A, Vagnani S et al (2013) Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol 32:1071–1073
9. Soo MP, Chow SK, Tan CT, Nadior N, Yeap SS, Hoh HB (2000) The spectrum of ocular involvement in patients with systemic lupus erythematosus without ocular symptoms. Lupus 9:511–514
10. Sitaula R, Shah DN, Singh D (2011) The spectrum of ocular involvement in systemic lupus erythematosus in a tertiary eye care center in Nepal. Ocul Immunol Inflamm 19:422–425
11. Yap EY, Au Eong KG, Fong KY, Howe HS, Boey ML et al (1998) Ophthalmic manifestations in Asian patients with systemic lupus erythematosus. Singapore Med J 39:557–559
12. Fraga MM, Len CA, Santos Finamor LP, Matos KT, Muccioli C et al (2011) Ocular changes due to the treatment of juvenile systemic lupus erythematosus. Rev Bras Reumatol 51:554–557
13. Al-Mayouf SM, Al-Hemidan AI (2003) Ocular manifestations of systemic lupus erythematosus in children. Saudi Med J 24:964–966
14. Chavez Villa M, Romero Diaz J, Recillas Gispert C, Lizana C, Cardenas F et al (2011) Risk factors associated with cataracts in systemic lupus erythematosus patients. An inception-Cohort Study [abstract]. Arthritis Rheum 63(Suppl 10):2272
15. Fong KY, Thumboo J, Koh ET, Chng HH, Leong KH et al (1997) Systemic Lupus Erythematosus: initial manifestations and clinical features after 10 years of disease. Ann Acad Med Singapore 26:278–281
16. Klejnberg T, Moraes Junior HV (2006) Ophthalmological alterations in outpatients with systemic lupus erythematosus. Arq Bras Oftalmol 69:233–237
17. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369
18. Shah M, Chaudhari S, McLaughlin TP, Kan HJ, Bechtel B et al (2013) Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus Erythematosus. Clin Ther 35:486–497
19. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119–1124
20. Skalka HW, Prchal JT (1980) Effect of corticosteroids on cataract formation. Arch Ophthalmol 98:1773–1777
21. Limaye SR, Pillai S, Tina LU (1988) Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol 20:225–227
22. Black RL, Oglesby RB, von Sallmann L, Bunim JJ (1960) Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 174:166–171
23. Gupta V, Awasthi N, Wagner BJ (2007) Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells. Invest Ophthalmol Vis Sci 48:1724–1734
24. Fel A, Aslangul E, Le Jeunne C (2012) Eye and corticosteroids use. Presse Med 41:414–421
25. Gladman DD, Ibañez D, Ruiz I, Urowitz MB (2013) Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 40:630–633
26. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Winchester RJ et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
27. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725
28. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550–2558
29. American Diabetes Association (2008) Diagnosis and classification of diabetes mellitus. Diabetes Care 31(Suppl 1):S55–S60
30. Pincus T, Castrejón I, Sokka T (2011) Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol 29:S130–S138
31. Waszczykowska A, Goś R, Waszczykowska E, Dziankowska-Bartkowiak B, Jurowski P (2013) Prevalence of ocular manifestations in systemic sclerosis patients. Arch Med Sci 30:1107–1113
32. Jobling AI, Augusteyn RC (2002) What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 85:61–75
33. Schaumberg DA, Glynn RJ, Christen WG, Ajani UA, Stürmer T et al (2001) Prospective study of blood pressure and risk of cataract in men. Ann Epidemiol 11:104–110
34. Richter GM, Torres M, Choudhury F, Azen SP, Varma R; Los Angeles Latino Eye Study Group (2012) Risk factors for cortical, nuclear, posterior subcapsular, and mixed lens opacities: the Los Angeles Latino Eye Study. Ophthalmology 119:547–554
35. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR et al (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (Clinical Research Ed.) 321:412–419
36. Leske MC, Wu SY, Nemesure B, Hennis A, Barbados Eye Studies Group (2002) Risk factors for incident nuclear opacities. Ophthalmology 109:1303–1308
37. Lu ZQ, Sun WH, Yan J, Jiang TX, Zhai SN, Li Y (2012) Cigarette smoking, body mass index associated with the risks of age-related cataract in male patients in northeast China. Int J Ophthalmol 5:317–322
38. Christen WG, Manson JE, Seddon JM, Glynn RJ, Buring JE et al (1992) A prospective study of cigarette smoking and risk of cataract in men. JAMA 268:989–993
39. Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rochtchina E et al (2002) Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol 155:997–1006